CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
101Patents
74Active
101Granted
52Portfolio score
Filing activity: May 22, 1991 → Mar 8, 2022 · 35 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5270177A | Method and apparatus for the production of glucose-fructose syrups from sucrose using a recombinant yeast strain | Chemistry; Metallurgy | 57 | Expired |
| US7556809B2 | Active antiangiogenic therapy | Human Necessities | 17 | Expired |
| US6905835B2 | Assay for anti transglutaminase antibodies detection useful in celicac disease diagnosis | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6146635A | System for the expression of heterologous antigens as fusion proteins | Emerging Cross-Sectional Technologies | 15 | Expired |
| US8703893B2 | Four branched dendrimer-PEG for conjugation to proteins and peptides | Human Necessities | 12 | Active |
| US6309873A | Streptokinase mutants | Chemistry; Metallurgy | 11 | Expired |
| US8722742B2 | Chemical compounds having antiviral activity against Dengue virus and other Flaviviruses | Emerging Cross-Sectional Technologies | 11 | Active |
| US7799760B2 | Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention | Human Necessities | 8 | Active |
| US5286484A | Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations | Chemistry; Metallurgy | 6 | Expired |
| US8431524B2 | Peptide antagonist of interleukin-15 activity | Human Necessities | 6 | Active |
| US6358933B1 | Formulation of nucleic acid and acemannan | Chemistry; Metallurgy | 5 | Expired |
| US6191114A | Immunological activity for a peptide of the limulus anti-LPS factor | Human Necessities | 5 | Expired |
| US7244411B2 | Method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixtures | Chemistry; Metallurgy | 5 | Expired |
| US7279164B2 | Chimeric proteins that induce effects directed against viruses | Emerging Cross-Sectional Technologies | 5 | Expired |
| US7374766B1 | Compositions containing virus-like particles as immunopotentiators administered through the mucosa | Chemistry; Metallurgy | 4 | Expired |
| US7465704B2 | Methods for enhancing healing of diabetic foot ulcers by injecting epidermal growth factor (EGF) | Human Necessities | 4 | Expired |
| US6383488B1 | Pre-M/M epitopes of dengue virus, synthetic peptides, chimeric proteins and their use | Emerging Cross-Sectional Technologies | 4 | Expired |
| US7736638B2 | Interleukin-15 antagonist peptide | Human Necessities | 4 | Expired |
| US7318927B2 | Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus | Chemistry; Metallurgy | 4 | Expired |
| US8871725B2 | Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs | Human Necessities | 3 | Active |
| US7361638B2 | Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect | Human Necessities | 3 | Expired |
| US7374767B2 | Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors | Chemistry; Metallurgy | 2 | Expired |
| US10104889B2 | Method for inducing resistance to diseases in plants | Human Necessities | 2 | Active |
| US6413759B1 | Streptokinase mutants | Chemistry; Metallurgy | 2 | Expired |
| US7790173B2 | Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus | Emerging Cross-Sectional Technologies | 2 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.